Biotech - Oncology
•324 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (324)
%
| Company | Market Cap | Price |
|---|---|---|
|
Soligenix's HyBryte for CTCL is a lead oncology asset, placing the company in Biotech - Oncology.
|
$5.48M |
$1.68
-5.08%
|
|
ERNA is developing oncology-focused cell therapies (ERNA-101) for cancer, aligning with Biotech - Oncology.
|
$5.38M |
$1.29
-5.47%
|
|
IMNN-001 is a DNA-based cancer immunotherapy targeting ovarian cancer, fitting Biotech - Oncology.
|
$5.23M |
$5.37
-0.56%
|
|
BriaCell is an oncology-focused biotech developing cancer immunotherapies for metastatic breast cancer (Bria-IMT, Bria-OTS).
|
$4.69M |
$12.40
-2.21%
|
|
Calidi Biotherapeutics is an oncology-focused biotech developing oncolytic virus platforms (NeuroNova, SuperNova, RedTail) aimed at systemic metastatic disease.
|
$4.11M |
$1.55
-1.90%
|
|
Biotech - Oncology focus in cancer diagnostics and biomarker analysis.
|
$3.94M |
$0.90
+5.28%
|
|
Can-Fite's core cancer-focused assets (Namodenoson for HCC and inflammatory disease targets) place the company in Biotech - Oncology.
|
$2.66M |
$0.53
-7.02%
|
|
Processa's core pipeline comprises Next Generation Cancer therapies (NGC-Cap, NGC-Gem, NGC-Iri) targeting oncology, identifying Biotech - Oncology as the primary investable theme.
|
$2.53M |
$0.21
+10.59%
|
|
The company operates in biotech focused on oncology diagnostics (lung cancer detection), fitting Biotech - Oncology as a core theme.
|
$2.23M |
$2.45
-3.16%
|
|
CTD program and oncology support (Mytesi) position Jaguar within the oncology therapeutics/supportive care space.
|
$2.11M |
$2.07
-5.91%
|
|
Ampligen and AIM's immuno-oncology pipeline position the company as a biotech oncology-focused player.
|
$1.93M |
$2.52
-3.45%
|
|
Platform/portfolio emphasis on oncology applications via the Hemopurifier aligns with Biotech - Oncology themes (cancer-focused tech/drug-device interfaces).
|
$1.79M |
$0.69
-5.90%
|
|
Core oncology-focused biotech developing radiation-sensitizing cancer therapies (Ropidoxuridine) and related HDAC inhibitors.
|
$1.67M |
$3.80
+6.74%
|
|
Lipella is a clinical-stage biotech developing liposomal drug formulations with oncology-relevant applications (e.g., bladder cancer program LP-50), aligning with Biotech - Oncology.
|
$1.63M |
$0.64
+16.28%
|
|
CERO Therapeutics operates in oncology using immunotherapy platforms (CER-T) with lead candidate CER-1236, placing it squarely in biotech Oncology.
|
$1.28M |
$3.31
-20.24%
|
|
Company operates in oncology diagnostics, focusing on cancer detection tests.
|
$1.02M |
$1.60
|
|
Company's strategic pivot is toward oncology therapeutics (MpBC/TNBC) with a pan-NOS inhibitor program.
|
$979059 |
$0.02
|
|
Company focuses on oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$703985 |
$0.02
-41.18%
|
|
APTEVO is an oncology-focused biotechnology company developing immunotherapies, aligning with Biotech - Oncology.
|
$636578 |
$1.57
-7.10%
|
|
Company's core focus is oncology with its LSD1 inhibitor seclidemstat and SP-3164 programs, placing it squarely in Biotech - Oncology.
|
$557349 |
$3.93
+0.51%
|
|
The pipeline explicitly mentions oncology as a target indication alongside autoimmune/dermatology programs.
|
$391060 |
$0.49
-7.89%
|
|
LadRx is a biopharmaceutical company focused on oncology with LADR-based drug conjugates (aldoxorubicin) and next-generation LADR candidates.
|
$297055 |
$0.60
-20.00%
|
|
Patent filings in oncology (glioma, hematologic malignancies) indicate biotech focus in cancer therapies.
|
$229298 |
$0.00
|
|
NuCana is a clinical-stage biotechnology company focused on oncology therapies, anchored by its proprietary ProTide technology and cancer drug candidates.
|
N/A |
$5.33
-10.72%
|
Showing page 4 of 4 (324 total stocks)
Loading industry metrics...
Loading comparison data...
